- Home
- CFFN vs GLUE Comparison
CFFN vs GLUE Comparison
Compare CFFN & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFFN | GLUE |
|---|---|---|
| Founded | 1893 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CFFN | GLUE |
|---|---|---|
| Price | $8.44 | $10.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $9.50 | ★ $26.88 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | $16,300,000.00 | ★ $123,672,000.00 |
| Revenue This Year | $7.98 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | ★ $16.70 | $72.42 |
| Revenue Growth | 6.54 | ★ 63.54 |
| 52 Week Low | $5.98 | $9.68 |
| 52 Week High | $9.26 | $25.77 |
Technical Indicators
Market Signals| Indicator | CFFN | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 44.41 |
| Support Level | $8.43 | $9.69 |
| Resistance Level | $8.76 | $12.00 |
| Average True Range (ATR) | 0.19 | 0.56 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 68.46 | 50.37 |
Price Performance
Historical ComparisonAbout CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).